Compare · ANNX vs NVO
ANNX vs NVO
Side-by-side comparison of Annexon Inc. (ANNX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANNX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 254.5x ANNX ($682.5M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for ANNX).
- NVO has more recent analyst coverage (25 ratings vs 13 for ANNX).
- Company
- Annexon Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $682.5M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 4
- Recent ratings
- 13
- 25
Annexon Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANNX
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- PRESIDENT AND CEO Love Douglas bought $99,829 worth of shares (26,065 units at $3.83), increasing direct ownership by 7% to 390,476 units (SEC Form 4)
- Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon to Participate in Upcoming September Investor Conferences
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 144 filed by Annexon Inc.
- Annexon upgraded by Citizens
- SEC Form 4 filed by Director Blumenkranz Mark S.
- SEC Form 3 filed by new insider Blumenkranz Mark S.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank